Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer

Sacituzumab govitecan (SG), the first antibody–drug conjugate (ADC) approved for triple-negative breast cancer, incorporates the anti-TROP2 antibody hRS7 conjugated to a topoisomerase-1 (TOP1) inhibitor payload. We sought to identify mechanisms of SG resistance through RNA and whole-exome sequencing...

Descripción completa

Detalles Bibliográficos
Autores principales: Coates, James T., Sun, Sheng, Leshchiner, Ignaty, Thimmiah, Nayana, Martin, Elizabeth E., McLoughlin, Daniel, Danysh, Brian P., Slowik, Kara, Jacobs, Raquel A., Rhrissorrakrai, Kahn, Utro, Filippo, Levovitz, Chaya, Denault, Elyssa, Walmsley, Charlotte S., Kambadakone, Avinash, Stone, James R., Isakoff, Steven J., Parida, Laxmi, Juric, Dejan, Getz, Gad, Bardia, Aditya, Ellisen, Leif W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Research Briefs
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8495771/
https://www.ncbi.nlm.nih.gov/pubmed/34404686
http://dx.doi.org/10.1158/2159-8290.CD-21-0702

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8495771/
https://www.ncbi.nlm.nih.gov/pubmed/34404686
http://dx.doi.org/10.1158/2159-8290.CD-21-0702

Ejemplares similares